推荐产品
等级
analytical standard
质量水平
产品线
PESTANAL®
保质期
limited shelf life, expiry date on the label
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
agriculture
environmental
包装形式
neat
SMILES字符串
ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl
InChI
1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
InChI key
JWBOIMRXGHLCPP-UHFFFAOYSA-N
基因信息
human ... CYP11A1(1583) , CYP11B1(1584)
正在寻找类似产品? 访问 产品对比指南
一般描述
2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).
应用
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
法律信息
PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
警示用语：
Warning
危险声明
危险分类
Carc. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
Martin Fassnacht et al.
The New England journal of medicine, 366(23), 2189-2197 (2012-05-04)
Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area
M Terzolo et al.
European journal of endocrinology, 169(3), 263-270 (2013-05-25)
Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting. To
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门